Brokerages Set Atossa Genetics Inc. (NASDAQ:ATOS) Target Price at $6.33

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received a consensus recommendation of “Hold” from the five research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $6.3333.

Several research firms recently weighed in on ATOS. Ascendiant Capital Markets upped their price objective on shares of Atossa Genetics from $7.75 to $8.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. Finally, Zacks Research cut shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th.

Institutional Trading of Atossa Genetics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in Atossa Genetics by 51.3% during the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after buying an additional 37,809 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Atossa Genetics in the second quarter valued at approximately $321,000. Catalyst Funds Management Pty Ltd acquired a new stake in Atossa Genetics during the 2nd quarter valued at approximately $49,000. Qube Research & Technologies Ltd raised its holdings in Atossa Genetics by 357.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after purchasing an additional 325,340 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Atossa Genetics in the 2nd quarter worth approximately $381,000. 12.74% of the stock is currently owned by institutional investors.

Atossa Genetics Stock Down 0.1%

Shares of Atossa Genetics stock opened at $0.68 on Friday. The stock has a market cap of $88.46 million, a P/E ratio of -2.85 and a beta of 1.09. Atossa Genetics has a 12-month low of $0.55 and a 12-month high of $1.29. The business’s 50 day moving average is $0.70 and its 200-day moving average is $0.80.

Atossa Genetics’s stock is scheduled to reverse split before the market opens on Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 30th.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). On average, sell-side analysts expect that Atossa Genetics will post -0.22 EPS for the current year.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.